Beta-3 Receptors Agonist Pipeline Insight Report, 2018 Edition - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Beta-3 Receptors Agonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Beta-3 Receptors Agonist - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Beta-3 Receptors Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Beta-3 Receptors Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Beta-3 Receptors Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

Provides a snapshot of the therapeutics pipeline activity for Beta-3 Receptors Agonist Features the Beta-3 Receptors Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Beta-3 Receptors Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Beta-3 Receptors Agonist

Key Topics Covered:

1. Report Introduction

2. Beta-3 Receptors Agonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Beta-3 Receptors Agonist

4. Comparative Analysis

5. Beta-3 Receptors Agonist Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

Other product profiles in the detailed report..

6. Beta-3 Receptors Agonist Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Astellas Pharma Europe Ltd Merck & Co GlaxoSmithKline sanofi-aventis

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2qw5sx/beta3_receptors?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005422/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 01:14 PM/DISC: 11/30/2018 01:14 PM


Update hourly